BCBS North Carolina

Does BCBS North Carolina cover Zepbound?

Quick answer · Weight Loss

BCBS North Carolina covers it only when the plan's benefit includes it on Employer / Commercial Insurance.

  • Employer / Commercial Insurance: Depends on your plan's benefit. Patient must have anti-obesity medication coverage benefits (criterion 7 of initial criteria; criterion 4 of continuation criteria)

Last verified July 16, 2026. Policy effective July 1, 2026. Source: Pa policy. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What BCBS North Carolina requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Patient must have anti-obesity medication coverage benefits (criterion 7 of initial criteria; criterion 4 of continuation criteria)

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (CVD, CAD, HTN, OSA, knee_osteoarthritis, T2DM, dyslipidemia, PCOS, NASH/NAFLD, asthma, and COPD)
  • BMI of 25 or higher for patients of Asian descent
  • 6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult weight loss — obesity (BMI >= 30)

All of:

  • Patient is 18 years of age or older
  • Diagnosis of obesity AND BMI >= 30 kg/m2
  • Requested medication will NOT be used concurrently with another GLP-1 receptor agonist
  • Requested medication will NOT be used concurrently with another weight loss medication
  • Provider has addressed requirement for lifestyle modifications
  • Patient has anti-obesity medication coverage benefits

Plus any one of:

  • Patient was unable to achieve acceptable weight loss (1 lb/week) through lifestyle modifications over 6 months
  • Patient has a weight-related comorbidity that warrants immediate medication intervention

Adult weight loss — Asian descent (BMI >= 25)

All of:

  • Patient is 18 years of age or older
  • Diagnosis of obesity AND BMI >= 25 kg/m2
  • Patient is of South Asian, Southeast Asian, or East Asian descent
  • Requested medication will NOT be used concurrently with another GLP-1 receptor agonist
  • Requested medication will NOT be used concurrently with another weight loss medication
  • Provider has addressed requirement for lifestyle modifications
  • Patient has anti-obesity medication coverage benefits

Plus any one of:

  • Patient was unable to achieve acceptable weight loss (1 lb/week) through lifestyle modifications over 6 months
  • Patient has a weight-related comorbidity that warrants immediate medication intervention

Adult weight loss — overweight with comorbidity (BMI >= 27)

All of:

  • Patient is 18 years of age or older
  • BMI >= 27 kg/m2
  • At least one weight-related comorbidity/risk factor (e.g., CVD, CAD, HTN, OSA, knee-osteoarthritis, T2DM, dyslipidemia, PCOS, NASH/NAFLD, asthma, COPD)
  • Requested medication will NOT be used concurrently with another GLP-1 receptor agonist
  • Requested medication will NOT be used concurrently with another weight loss medication
  • Provider has addressed requirement for lifestyle modifications
  • Patient has anti-obesity medication coverage benefits

Plus any one of:

  • Patient was unable to achieve acceptable weight loss (1 lb/week) through lifestyle modifications over 6 months
  • Patient has a weight-related comorbidity that warrants immediate medication intervention

Documentation to bring

  • Baseline BMI documentation
  • Documentation of obesity diagnosis or weight-related comorbidity
  • For Asian descent patients: documentation of ancestry (South Asian, Southeast Asian, or East Asian)
  • Documentation that provider addressed lifestyle modification requirement
  • Documentation of 6-month lifestyle modification attempt with failure to achieve 1 lb/week weight loss, OR documentation of weight-related comorbidity warranting immediate medication intervention
  • Documentation that patient is not concurrently using another GLP-1 receptor agonist
  • Documentation that patient is not concurrently using another weight loss medication
  • Confirmation of anti-obesity medication coverage benefits

Quantity limits

  • 2.5 mg/0.5 mL — 4 pens per 28 days

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight and Adults: weight loss >= 5% from baseline (prior to initiation). Patient must retain anti-obesity medication coverage benefits. Initial BMI, lifestyle, and comorbidity criteria are not re-verified at continuation. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Concurrent use of another GLP-1 receptor agonist
  • Concurrent use of another weight loss medication
  • Non-formulary products require Non-formulary Exception Criteria

Policy note: Zepbound added to policy November 2023. Step requirement removed April 2024. Only the 2.5mg titration dose has an explicit quantity limit; maintenance doses do not have a listed quantity limit per May 2024 update. Zepbound does not have a listed pediatric (12-17) indication in this policy. Quantity limit exception criteria allows a 90-day titration period override.

Policy effective July 1, 2026 · verified July 16, 2026 · source: Pa policy

Zepbound for Osa

What BCBS North Carolina requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Patient must have anti-obesity medication coverage benefits (criterion 7 of initial criteria; criterion 4 of continuation criteria)

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • 6 months of a documented diet and exercise program
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

OSA in adults with obesity

All of:

  • Patient is 18 years of age or older
  • Diagnosis of moderate to severe obstructive sleep apnea
  • BMI >= 30 kg/m2
  • Polysomnography (PSG) or home sleep apnea test performed
  • Apnea hypopnea index (AHI) >= 15 at baseline
  • Requested medication will NOT be used concurrently with another GLP-1 receptor agonist
  • Requested medication will NOT be used concurrently with another weight loss medication
  • Provider has addressed requirement for lifestyle modifications
  • Patient has anti-obesity medication coverage benefits

Plus any one of:

  • Patient was unable to achieve acceptable weight loss (1 lb/week) through lifestyle modifications over 6 months
  • Patient has a weight-related comorbidity (e.g., OSA) that warrants immediate medication intervention

Documentation to bring

  • Documentation of moderate to severe obstructive sleep apnea diagnosis
  • Baseline BMI >= 30 kg/m2
  • Polysomnography (PSG) or home sleep apnea test results showing AHI >= 15 at baseline
  • Documentation that provider addressed lifestyle modification requirement
  • Documentation of 6-month lifestyle modification attempt with failure to achieve 1 lb/week weight loss, OR documentation of OSA as weight-related comorbidity warranting immediate medication intervention
  • Documentation that patient is not concurrently using another GLP-1 receptor agonist
  • Documentation that patient is not concurrently using another weight loss medication
  • Confirmation of anti-obesity medication coverage benefits

Quantity limits

  • 2.5 mg/0.5 mL — 4 pens per 28 days

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for Patient with OSA must demonstrate a positive clinical response while using the medication. No weight loss percentage threshold required for continuation of OSA indication.

Not covered when

  • Concurrent use of another GLP-1 receptor agonist
  • Concurrent use of another weight loss medication

Policy note: OSA indication for Zepbound added January 2025, criteria updated April 2025. Policy requires AHI >= 15 (moderate OSA threshold) confirmed by PSG or home sleep apnea test. No PAP therapy trial requirement stated. The OSA pathway requires BMI >= 30 (not BMI >= 27 with comorbidity). Continuation for OSA requires positive clinical response rather than a specific weight loss percentage. The lifestyle modification criteria (items 3-6) from the broader initial criteria section apply to all drugs in the Foundayo/Saxenda/Wegovy/Zepbound group including OSA indication.

Policy effective July 1, 2026 · verified July 16, 2026 · source: Pa policy

Why Zepbound requests get denied by BCBS North Carolina

Based on what this policy asks for. Fix these before the first submission.

  1. Your specific plan doesn't include the weight loss benefit. Coverage here is conditional on the benefit design (often an optional employer add-on), so confirm it before submitting.
  2. Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
  3. BMI not documented in the chart notes (or documented without a baseline weight and date).
  4. Qualifying weight-related condition not documented with its own diagnosis code.
  5. No documented diet and exercise program.
  6. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

If weight loss isn't covered on your plan

BCBS North Carolina has separate Zepbound policies that don't depend on the weight loss benefit:

  • Osa — covered on Employer / Commercial Insurance.

Zepbound is also sold directly by Eli Lilly without insurance through LillyDirect.

Frequently asked questions

Does BCBS North Carolina cover Zepbound?
BCBS North Carolina covers it only when the plan's benefit includes it on Employer / Commercial Insurance.
What BMI do you need for Zepbound under BCBS North Carolina?
For weight loss on Employer / Commercial Insurance plans, BCBS North Carolina requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition.
How long does a Zepbound approval last with BCBS North Carolina?
Initial approvals last 6 months, and renewals are granted in 12-month periods.
What does BCBS North Carolina require to renew Zepbound?
At least 5% weight loss from the starting weight and Adults: weight loss >= 5% from baseline (prior to initiation). Patient must retain anti-obesity medication coverage benefits. Initial BMI, lifestyle, and comorbidity criteria are not re-verified at continuation.
What if my plan excludes weight loss medications?
BCBS North Carolina has separate Zepbound policies for osa, which are covered on some plan types and don't depend on the weight-loss benefit. Zepbound is also available for cash through LillyDirect.
How current is this information?
This page reflects BCBS North Carolina's written policy as of July 1, 2026, last verified against the source document on July 16, 2026.

Other medications under BCBS North Carolina

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes BCBS North Carolina's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.